Tag: gene therapy
RTW Biotech Opportunities joins $160.5m Series C of Obsidian Therapeutics
RTW Biotech Opportunities Ltd, an investment company listed on the London Stock Exchange and specialized in the life sciences sector, is proud to announce its ... Read More
Merck announces over €300m investment in new bioprocessing center in South Korea
Merck has embarked on a monumental investment venture, injecting more than €300 million into the construction of a new Bioprocessing Production Center located in Daejeon, ... Read More
Ginkgo Bioworks acquires Proof Diagnostics to boost cell programming and biosecurity capabilities
Ginkgo Bioworks, a leader in cell programming and biosecurity, announced its acquisition of Proof Diagnostics, a trailblazer in life sciences tools, diagnostics, and computational discovery. ... Read More
Andelyn Biosciences, Armatus Bio to accelerate gene therapy for CMT1A
Andelyn Biosciences, Inc., a leading Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapy, has announced a significant partnership with Armatus Bio ... Read More
bluebird bio unveils US commercial strategy for LYFGENIA gene therapy
bluebird bio, Inc., a pioneer in the biotechnology industry, has announced the U.S. commercial infrastructure for LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel), an FDA-approved ... Read More
XyloCor reveals promising 12-month data from Phase 2 Trial of XC001
XyloCor Therapeutics, a clinical-stage biopharmaceutical company focusing on novel gene therapies for cardiovascular diseases, has revealed encouraging 12-month data from the Phase 2 section of ... Read More
Laurus Labs expands stake in Immunoadoptive Cell Therapy for Rs.80cr
Hyderabad-based pharmaceutical company Laurus Labs has announced a significant investment in Immunoadoptive Cell Therapy (lmmunoACT), an advanced cell and gene therapy firm. The deal, valued ... Read More
CSL Behring bags Hemgenix EC approval for treatment of Hemophilia B
German-based biotechnology company CSL Behring has received conditional marketing authorization (CMA) from the European Commission (EC) for its Hemgenix (etranacogene dezaparvovec) indicated for the treatment ... Read More
CSL Behring gets Hemgenix FDA approval for hemophilia B
CSL Behring, a US-based biotechnology company, has received approval for its Hemgenix (etranacogene dezaparvovec-drlb) from the US Food and Drug Administration (FDA) as a one-time ... Read More
Genprex begins dosing of phase 1/2 trial of REQORSA, Tagrisso combo
Genprex has dosed the first patient in the Acclaim-1 phase 1/2 clinical trial of REQORSA immunogene therapy candidate in combination with Tagrisso (osimertinib) in a ... Read More